WindMIL Therapeutics Opens Combination Therapy Portion Of Its Phase 2a Clinical Trial Of Marrow-Infiltrating Lymphocytes (MILs) For Treatment Of Patients With Non-Small Cell Lung Cancer
Benzinga Newsdesk